The Biosimilar Red Tape Elimination Act aims to reduce regulatory barriers and administrative burdens associated with the approval and market entry of biosimilar drugs. By streamlining processes, the bill seeks to promote competition in the pharmaceutical market, potentially lowering drug prices and increasing patient access to these biologic medications.